Celgene

3 Potential New Drugs Held Up by the Shutdown
3 Potential New Drugs Held Up by the Shutdown
Motley Fool
FDA
government shutdown
Aimmune Therapeutics
AR 101
Celgene
fedratinib
Bristol-Myers Squibb
ozanimod
Flag link:
Celgene strikes Obsidian deal to boost CAR-T options
Celgene strikes Obsidian deal to boost CAR-T options
Fierce Biotech
Celgene
Obsidian Therapeutics
CAR-T
Flag link:
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
Ahead of Bristol Myers purchase, Celgene partners with Boston cancer startup
Bizjournals
Celgene
drug development
Kyn Therapautics
cancer
Flag link:
Acceleron, Stemline price upsized follow-ons
Acceleron, Stemline price upsized follow-ons
BioCentury
Acceleron
Stemline Therapeutics
Celgene
Elzonris tagraxofusp-erzs
Flag link:
Smaller groups await Bristol-Myers Squelgene fallout
Smaller groups await Bristol-Myers Squelgene fallout
EP Vantage
M&A
Bristol-Myers Squibb
Celgene
Vividion Therapeutics
Evotec
Prothena
Anokion
Skyhawk Therapeutics
Dragonfly Therapeutics
BeiGene
Agios Pharmaceuticals
Jounce Therapeutics
Flag link:
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices
Congressmen to regulators: BMS-Celgene merger will stifle competition and raise drug prices
Fierce Pharma
US Congress
M&A
Bristol-Myers Squibb
Celgene
drug pricing
Flag link:
NASH Space in Focus in 2019 as Firms Look to Diversify
NASH Space in Focus in 2019 as Firms Look to Diversify
Yahoo/Zacks.com
NASH
Gilead Sciences
Merck
Roche
Novartis
Jecure Therapeutics
Pfizer
Celgene
Eli Lilly
Flag link:
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
JPM recap: Must-reads of the week, from FDA to IPO to M&A and more
Fierce Pharma
JPMHC 2019
Merck
FDA
M&A
Celgene
Bristol-Myers Squibb
Genevant
IPOs
Eli Lilly
Novartis
GSK
Teva Pharmaceutical
Alexion
Pear Therapeutics
Flag link:
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
Xconomy
Celgene
M&A
Juno Therapeutics
Kite Therapeutics
Bluebird Bio
Agios Pharmaceuticals
Jounce Therapeutics
BieGene
Acceleron
Flag link:
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
Day One of JPM Brings Excitement and Promise for a New Year in Biotech and Pharma
BioSpace
JPMHC 2019
M&A
Eli Lilly
Loxo Oncology
SAGE Therapeutics
Sanofi
Regeneron
Bristol-Myers Squibb
Celgene
Novartis
Gilead Sciences
Flag link:
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
3 Things Bristol-Myers Squibb Understands About Celgene That the Market Hasn't
Motley Fool
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
Flag link:
Celgene invested $30M in NantCell weeks before BMS bid
Celgene invested $30M in NantCell weeks before BMS bid
BioCentury
Celgene
NantCell
Bristol-Myers Squibb
M&A
Flag link:
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
Why the Bristol-Myers Squibb Acquisition Is a Bad Deal for Celgene
Motley Fool
Bristol-Myers Squibb
Celgene
M&A
Flag link:
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
After Bristol-Myers Squibb Buys Celgene What's Next? JP Morgan's Conference Will Answer That
Forbes
Celgene
Bristol-Myers Squibb
M&A
JPMHC 2019
Flag link:
BMS CEO Giovanni Caforio Lays out Reasoning for $74 Billion Acquisition of Celgene
BMS CEO Giovanni Caforio Lays out Reasoning for $74 Billion Acquisition of Celgene
BioSpace
Bristol-Myers Squibb
M&A
Giovanni Caforio
Celgene
Flag link:
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Could Gilead, Amgen and AbbVie follow Bristol-Myers into megadeal territory?
Fierce Pharma
M&A
Bristol-Myers Squibb
Celgene
Gilead Sciences
AbbVie
Amgen
Flag link:
Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal
Celgene executives whipped up new, lucrative severance plans ahead of Bristol-Myers megadeal
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
severance
executive pay
Flag link:
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
The BMS-Celgene merger’s Achilles heel? An earlier-than-expected Revlimid patent loss
Fierce Pharma
Bristol-Myers Squibb
Celgene
M&A
Revlimid
patents
Flag link:
Should Celgene Investors Take Bristol's Money and Run?
Should Celgene Investors Take Bristol's Money and Run?
Motley Fool
Celgene
Bristol-Myers Squibb
M&A
Flag link:
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Here’s What Bristol-Myers Squibb Will Look Like After Acquiring Celgene
Yahoo/Motley Fool
M&A
Celgene
Bristol-Myers Squibb
Flag link:

Pages